At Akamis Bio, we are unwearying in pursuit of our mission to positively impact the lives of people living with cancer.
PsiOxus Therapeutics has changed its name to Akamis Bio.
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer. To achieve that mission, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer.
Akamis Bio has a growing pipeline of T-SIGn® therapeutics anchored by our two clinical stage programs, NG-350A and NG-641. We have an extensive and growing body of clinical experience with T-SIGn® therapeutics with more than 200 patients treated across both the monotherapy setting, as well as in combination with checkpoint inhibitors. Across our clinical studies, T-SIGn® therapeutics have demonstrated a consistent safety & tolerability profile, as well as promising preliminary evidence of clinical activity.